Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 16:55:00 13/03/2026 GMT			5-day change	1st Jan Change
76.39 ^EUR	-0.17%		-1.72%	-7.65%

03-10	Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit	RE
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE

Sanofi Names Belen Garijo to Replace Paul Hudson as CEO

Published on 02/12/2026 at 07:14 am GMT

Dow Jones

SANOFI

-0.17%

MERCK KGAA

-1.51%

By Billy Gray

Sanofi said Belen Garijo would succeed Paul Hudson as chief executive officer after the company's board of directors decided not to renew Hudson's mandate.

The French drugmaker said the decision to replace Hudson as CEO came in a board meeting on Feb. 11. Garijo will step into the top role at the end of the group's annual general meeting on April 29, while Hudson is set to step down on Feb. 17 at the close of business.

Sanofi thanked Hudson for his contributions to the company over the past six years.

Garijo has since 2021 been the CEO of Merck KGaA, which she joined in 2011. She previously worked for 15 years at Sanofi, where she was vice president of pharmaceutical operations for Europe and Canada and a member of the executive committee.

Olivier Charmeil, Sanofi's executive vice president, general medicines, will serve as interim CEO during the leadership transition, the company said.

Write to Billy Gray at william.gray@wsj.com

(END) Dow Jones Newswires

02-12-26 0210ET

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	SANOFI	76.39EUR	-0.17%	-1.72%	107B
	MERCK KGAA	107.80EUR	-1.51%	-4.77%	54.85B

Latest news about Sanofi

03-10	Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit	RE
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE
03-09	Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study	RE
03-06	Brazil's EMS purchases Sanofi's Medley in deal worth over $500 million	RE
03-06	Brazil's EMS purchases Sanofi's Medley	RE
03-05	EMS S.A. announced the signing of a definitive agreement to acquire Sanofi Medley Farmacêutica Ltda. from Sanofi.	CI
03-05	Merck Outlook Disappoints – MS Drug Patent Loss Weighs on Forecast	RE
03-05	Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee	CI
03-05	Germany's Merck KGaA Expects Currency Headwinds to Weigh on Earnings	DJ
03-04	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
03-04	Euroapi
03-04	Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals	DJ
03-04	Sino Biopharm Unit Signs Global License Deal With Sanofi for Rovadicitinib	MT
03-04	Sino Biopharm Inks Up to $1.5 Billion Deal With Sanofi for Cancer Treatment	DJ
03-03	Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion	RE

Paul Hudson

Mr. Paul Hudson is a Chief Executive Officer & Director at Sanofi, a Chairman at Novartis Pharma KK and a Chief Executive Officer & Director at Sanofi Clir SENC. He is on the Board of Directors at Sanofi and Sanofi Clir SENC. Mr. Hudson was previously employed as a Chief Executive Officer by Novartis Pharmaceuticals Corp., a President-AstraZeneca US & EVP-North America by AstraZeneca Plc, a President by AstraZéneca Farmacéutica Spain SA, a President & Director by AstraZeneca KK, a Member-Executive Committee by Novartis AG, and a Head-Global Marketing by Schering Plough Holdings France SAS. He received his undergraduate degree from Manchester Metropolitan University of.

View full profile

Chart Sanofi

Duration

Period

SAN: Dynamic Chart

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).

Employees

74,846

Sector

Pharmaceuticals

Calendar

04-23 - Earnings release - Q1 2026

More about the company